Agenus Inc. (NASDAQ:AGEN) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lessened its stake in Agenus Inc. (NASDAQ:AGEN) by 1.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,036,876 shares of the biotechnology company’s stock after selling 18,053 shares during the period. Charles Schwab Investment Management Inc. owned about 0.55% of Agenus worth $3,298,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Greenwich Wealth Management LLC purchased a new position in shares of Agenus during the fourth quarter worth $38,000. The Manufacturers Life Insurance Company boosted its holdings in Agenus by 13.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 97,781 shares of the biotechnology company’s stock valued at $311,000 after acquiring an additional 11,554 shares during the period. Credit Suisse AG grew its position in Agenus by 29.7% in the 4th quarter. Credit Suisse AG now owns 359,652 shares of the biotechnology company’s stock valued at $1,143,000 after acquiring an additional 82,257 shares in the last quarter. Barclays PLC grew its position in Agenus by 8.1% in the 4th quarter. Barclays PLC now owns 75,114 shares of the biotechnology company’s stock valued at $239,000 after acquiring an additional 5,604 shares in the last quarter. Finally, Citigroup Inc. lifted its position in shares of Agenus by 150.7% during the fourth quarter. Citigroup Inc. now owns 37,363 shares of the biotechnology company’s stock worth $119,000 after purchasing an additional 22,460 shares in the last quarter. Institutional investors own 53.35% of the company’s stock.

Shares of NASDAQ:AGEN opened at $2.68 on Wednesday. Agenus Inc. has a 52 week low of $2.28 and a 52 week high of $5.95. The company’s 50 day moving average is $3.00 and its two-hundred day moving average is $3.63. The company has a market cap of $547.53 million, a PE ratio of -2.45 and a beta of 1.86.

Agenus (NASDAQ:AGEN) last issued its earnings results on Sunday, March 14th. The biotechnology company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. The firm had revenue of $31.27 million for the quarter, compared to analyst estimates of $16.23 million. As a group, research analysts expect that Agenus Inc. will post -1.07 earnings per share for the current fiscal year.

A number of equities research analysts have issued reports on AGEN shares. B. Riley reiterated a “buy” rating and set a $8.00 target price on shares of Agenus in a report on Friday, January 15th. Zacks Investment Research lowered Agenus from a “hold” rating to a “sell” rating in a report on Thursday, April 1st.

About Agenus

Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

Recommended Story: What is an overbought condition?

Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agenus Inc. (NASDAQ:AGEN).

Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.